Synthesis and Antistaphylococcal Activity of<i>N</i>-Substituted-1<i>H</i>-benzimidazole-sulphonamides
作者:M. Orhan Püsküllü、Sulhiye Yıldız、Hakan Göker
DOI:10.1002/ardp.200900199
日期:2009.11.19
evaluated for antibacterial activity against Staphylococcus aureus and methicillin‐resistant S. aureus (MRSA). Certain compounds inhibit bacterial growth with low MIC (μg/mL) values. The most active compounds 30, 31, and 32 have the lowest MIC values with 0.39 to 0.19 μg/mL. Among the compounds having sulfonamido moities, 16, 23, and 24 exhibited the strongest antibacterial activity with 1.56 μg/mL MIC values
Synthesis and<i>In Vitro</i>Activity of Polyhalogenated 2-phenylbenzimidazoles as a New Class of anti-MRSA and Anti-VRE Agents
作者:Hakan Göker、Cigdem Karaaslan、Mustafa Orhan Püsküllü、Sulhiye Yildiz、Yalcin Duydu、Aylin Üstündağ、Can Özgür Yalcin
DOI:10.1111/cbdd.12623
日期:2016.1
A series of novel polyhalogenated 2‐phenylbenzimidazoles have been synthesized and evaluated for in vitro antistaphylococcal activity against drug‐resistant bacterial strains (methicillin‐resistant Staphylococcus aureus, and vancomycin‐resistant Enterococcus faecium. Certain compounds inhibit bacterial growth perfectly. 11 was active than vancomycin (0.78 μg/mL) with the lowest MIC values with 0.19 μg/mL against methicillin‐resistant Staphylococcus aureus, 8 and 35 exhibited best inhibitory activity against vancomycin‐resistant Enterococcus faecium (1.56 μg/mL). The mechanism of action for this class of compounds appears to be different than clinically used antibiotics. These polyhalogenated benzimidazoles have potential for further investigation as a new class of potent anti‐methicillin‐resistant Staphylococcus aureus and anti‐vancomycin‐resistant Enterococcus faecium agents.
Synthesis and Potent In vitro Activity of Novel 1H-Benzimidazoles as Anti-MRSA Agents
A new class of 1H‐benzimidazolecarboxamidines was synthesized and evaluated for in vitro antibacterial and antifungal activities, including drug‐resistant bacterial strains. The most potent compound (32) has the same ratio of anti‐MRSA activity as Vancomycin (minimal inhibitory concentrations value 0.78 μg/mL). The mechanism of action for 1H‐benzimidazolecarboxamidine appears to be different from existing antibacterial agents. These compounds have potential for development as a new class of potent anti‐MRSA agent.